Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnostic kit for early assessment of risk of adverse reactions to chemotherapy of taxanes

A diagnostic kit and taxane technology, applied in the fields of genetic engineering and oncology, can solve the problems of inaccurate use of Chinese Han population for clinical medication guidance, different gene frequencies, and different SNP loci distribution, etc. Realize individualized treatment guidance, improve efficacy and safety, and quickly and accurately grasp the effect of patients' conditions

Inactive Publication Date: 2019-05-14
济南市第四人民医院
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The distribution of some SNP sites is different in different races. For example, most of the previous myelosuppression studies were done in the Caucasian population. The results of the study may not be applicable to Han patients because the gene frequencies of the two races are not exactly the same. It cannot be accurately used to guide clinical medication in the Chinese Han population, and the results of previous myelosuppression studies need to be further verified in the Chinese Han population

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic kit for early assessment of risk of adverse reactions to chemotherapy of taxanes
  • Diagnostic kit for early assessment of risk of adverse reactions to chemotherapy of taxanes
  • Diagnostic kit for early assessment of risk of adverse reactions to chemotherapy of taxanes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] This embodiment includes sample collection and sorting, genomic DNA sample preparation, genotype detection, statistical analysis and result analysis.

[0021] 1. Sample collection and arrangement

[0022] From 2012 to 2015, a large number of blood samples of cancer patients were collected from the Fourth People's Hospital of Jinan City. After sorting out the sample data, 124 samples meeting the following criteria were selected: (1) cancer patients aged 18 to 80 Patients; (2) no major organ dysfunction, blood routine, liver and kidney function and heart function were basically normal before the first chemotherapy; (3) all patients received at least one cycle of chemotherapy based on paclitaxel or docetaxel; (4) except In patients with bone metastases, all patients had a baseline absolute neutrophil count greater than 1.5×10 9 / L; (5) Baseline information such as age, gender, height, weight, tumor type, and tumor stage of the patient; (6) Detailed information on drug tox...

Embodiment 2

[0040] This embodiment is the application of a diagnostic kit based on PCR technology and DNA sequencing technology.

[0041] 1. DNA extraction

[0042] DNA was extracted from peripheral blood using the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) according to the product instructions, and stored at -20°C.

[0043] 2. PCR reaction

[0044] Use the PCR reaction kit from the diagnostic kit, which contains the following primer pairs:

[0045] The sequence of the front primer of SLC15A1rs2297322 is SEQ ID NO:1, and the sequence of the back primer is SEQ ID NO:2;

[0046] The sequence of the front primer of UGT1A1rs4148323 is SEQ ID NO:3, and the sequence of the back primer is SEQ ID NO:4;

[0047] The sequence of the front primer of NR1I2rs3732359 is SEQ ID NO:5, and the sequence of the back primer is SEQ ID NO:6;

[0048] The sequence of the front primer of HNF4αrs6130615 is SEQ ID NO:7, and the sequence of the back primer is SEQ ID NO:8.

[0049] For details of the ab...

Embodiment 3

[0067] This example provides taxane chemotherapy drug-related myelosuppression risk gene detection services.

[0068] 1. DNA extraction

[0069] Blood samples were collected from the subjects by laboratory physicians in the hospital, and genomic DNA was extracted from whole blood using the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of genetic engineering and oncology, and discloses a diagnostic kit for early assessment of the risk of adverse reactions of chemotherapy of taxanes. The kit is usedfor predicting the risk of myelosuppression in a subject caused by chemotherapy drugs of taxanes. The kit comprises four pairs of SNPs locus genotype specific amplification primers and four specificextension primers, and targeted detection genes include a drug transporter gene SLC15A1, a drug metabolism gene UGT1A1, a nuclear receptor gene NR1I2 and a nuclear receptor gene HNF4alpha. The detection locus used in the kit is a susceptible SNPs for myelosuppression associated with the chemotherapy drugs of the taxanes. By detecting, the occurrence risk of taxane-related myelosuppression can be effectively evaluated, and the precise administration of the taxanes can be promoted.

Description

Technical field: [0001] The invention belongs to the fields of genetic engineering and oncology, and relates to a diagnostic kit for early assessment of the risk of taxane drug chemotherapy adverse reactions. Background technique: [0002] Taxanes, including paclitaxel and docetaxel, are widely used in the standard treatment of a variety of solid tumors, such as breast, ovarian, pancreatic, gastric, non-small cell lung, and head and neck cancers. However, taxanes often cause adverse drug reactions during cancer treatment, such as myelosuppression, peripheral neuropathy, and gastrointestinal toxicity. In particular, myelosuppression occurs in approximately 80% of taxane-treated patients and is one of the leading reasons for discontinuation of taxane therapy. [0003] Myelosuppression refers to decreased blood cells, including neutropenia, leukopenia, anemia, or thrombocytopenia. Among them, neutropenia is the most common in taxane therapy. Since the red blood cells and whi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883
Inventor 郭亮荆强史鑫周晨希
Owner 济南市第四人民医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com